Here are five takeaways:
1. From 2016 to 2020, the market is projected to increase at a compound annual growth rate of 4.97 percent.
2. An influx of research and development activities will spur market growth.
3. The growing aging population is also driving market growth, with the number of people aged 60 years and above to reach 32 percent by 2050.
4. A growing preference for alterative therapies will pose a challenge to market growth.
5. Key market vendors include AstraZeneca, Endo International, Johnson & Johnson, Pfizer and Purdue Pharma, among others.
More articles on spine:
4 observations of relationship between pedicle screw fixation strength & bone material density
Women report inferior outcomes in lumbar spinal fusions: 5 key notes
Drs. Joshua Bederson, Robert Fink & more: 4 spine surgeons in the headlines this week — August 5, 2016
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
